Washington, July 30 : A team of researchers from Weill Cornell Medical College and Columbia University Medical Center has found out how antidepressant drugs, cocaine, and amphetamines interact with brain cells.
The researchers say that their breakthrough research may pave the way for more targeted medication therapies for a host of psychiatric diseases, most notably in the area of addiction.
"These findings are so clear and detailed at the level of molecular behaviour that they will be most valuable to developing more effective therapies for mood disorders and neurologic and psychiatric diseases, and to direct effective treatments for drug addiction to cocaine and amphetamines," says co-lead author Dr. Harel Weinstein, Chairman and Maxwell M. Upson Professor of Physiology and Biophysics, and director of the HRH Prince Alwaleed Bin Talal Bin Abdulaziz Al-saud Institute for Computational Biomedicine at Weill Cornell Medical College.
"This research may also open the door to the development of new therapies for dopamine-neurotransmitter disorders such as Parkinson's disease, schizophrenia, and anxiety and depression," the researcher adds.
The findings have been reported in two research articles that have been published separately in the journals Molecular Cell and Nature Neuroscience.
In one study, the researchers mapped the precise molecular and biochemical structure of drug targets known as neurotransmitter-sodium symporters (NSSs), and discovered how cells use them to enable neural signalling in the brain.
In the second study, they pinpoints where the drug molecules bind in the neurotransmitter transporter - their target in the human nervous system.
During the first study, Dr. Jonathan Javitch and his colleagues stabilized different structural states of the neurotransmitter-sodium-symporter molecule that relate to steps in its function, which allowed them to study how substrates and inhibitors affect the transition between these different states, and thus to understand the way in which its function is accomplished.
"Crystallography had allowed the identification of only one structural form of the molecule, but our experiments and computations were able to identify how this form changes and thereby add an understanding of the functional role of the different forms that the molecule must adopt to accomplish transport activity," says Dr. Javitch.
The main surprise was the realization that two binding sites on the transporter molecule need to be filled simultaneously, and cooperate in order for transport to be driven across the cell membrane.
For these studies, the scientists used the crystal structure of a bacterial transporter that is very similar to human neurotransmitter transporters, and performed computer simulations to reveal the path of the transported molecules into cells.
Laboratory experimentation was used to test the computational predictions and validate the researchers' inferences.
Together, the procedures revealed a finely-tuned process in which two sodium ions bind and stabilize the transporter molecule for the correct positioning of the two messenger molecules - one deep in the center of the protein, and the other closer to the entrance.
Like a key engaging a lock mechanism, this second binding causes changes in the transporter throughout the structure, allowing one of the two sodium molecules to move inward, and then release the deeply bound messenger and its sodium partner into the cell.
In the bacterial transporter studied, antidepressant molecules bind in the outer one of two sites, and stop the transport mechanism, leaving the messenger molecule outside the cell.
The second research team found that in the human dopamine transporter cocaine binds in the deep site, unlike the antidepressant binding in the bacterial transporter.
Based on their observations, the researchers came to the conclusion that anti-cocaine therapy will be more complicated, because interfering with cocaine binding also means interference with the binding of natural messengers.
"This finding might steer anti-cocaine therapy in a completely new direction," says Dr. Weinstein.